You are here: Home James L. Wittliff, Ph.D.

James L. Wittliff, Ph.D.

by Wittliff,James L. last modified Oct 11, 2013 03:39 PM

Professor of Biochemistry & Molecular Biology & Brown Cancer Center

WittliffEmail:  jim.wittliff@louisville.edu
Phone Numbers: 502-852-5216 (Office) & 502-852-5694 (Lab)
Fax Number: 502-852-8008
Address: Health Sciences Center, Bldg. A, Room 604
    School of Medicine, Louisville, KY 40292
Ph. D., The University of Texas

 

 

 

Additional Appointments:

  • Director, Institute for Molecular Diversity & Drug Design (IMD3)

 

Investigators:

  • Sarah A. Andres, Ph.D., Post-doc
  • Sean T. Butterbaugh, Undergraduate
  • Adrienne M. Bushau, Undergraduate
  • Meredith L. Cundiff, High School Student

 

Staff:

  • Mitzie Wittliff, Administrative Assistant

 

Research Interests:

Dr. Wittliff and his team in the Hormone Receptor Laboratory are investigating the mechanisms by which steroid and peptide hormones induce their target cells to synthesize gene products and regulate biological networks. The kinetic and molecular properties of specific binding proteins (receptors) for steroid and peptide hormones are studied with regard to their functional role in responsive organs such as breast, colon, lung, ovary, uterus and their carcinomas. For more than four decades, Dr. Wittliff’s research program has investigated the biological properties and cellular roles of estrogen and progestin receptors in human cancers with the goal of improving their diagnostics and treatment. This includes the actions of estrogen mimics that may act as Endocrine Disruptor Compounds (EDCs). The role of epidermal growth factor receptor and a related protein, which is the product of the c-erb B-2 oncogene, are also being evaluated in the carcinomas of these organs. Currently, Hormone Receptor Laboratory members are examining the genomics and proteomics of specific cell types isolated by the technology of laser capture microdissection to ascertain the relationship between gene and protein expression profiles in human carcinomas and clinical outcome. His research is directed toward the discovery and dissemination of new knowledge as well as the filing of patents for technology developments.

 

Selected Publications:

    1. Andres, S.A., Wittliff, J.L. Relationships of ESR1 and XBP1 Expression in Human Breast Carcinoma and Stromal Cells Isolated by Laser Capture Microdissection Compared to Intact Breast Cancer Tissue. Endocrine 40:212-221, 2011.
    2. Andres, S.A., Edwards, A.B., Wittliff, J.L. Expression of Urokinase-Type Plasminogen Activator (uPA), Its Receptor (uPAR) and Inhibitor (PAI-1) in Human Breast Carcinomas and Their Clinical Relevance. J Clin Lab Anal 26:93-103, 2012.
    3. Andres, S.A., Wittliff, J.L. Co-expression of Genes with Estrogen Receptor-α and Progesterone Receptor in Human Breast Carcinoma Tissue. Horm Mol Biol Clin Investig 12:377-390, 2012.
    4. Andres, S.A., Bumpus, S.B., Wittliff, J.L. Assessment of Phytoestrogen and Mycoestrogen Recognition by Recombinant Human Estrogen Receptor-α Using Ligand Titration Arrays. Phytochem Anal 24:357-366, 2013.
    5. Andres, S.A., Wittliff, J.L., Cheng, A. Protein Tyrosine Phosphatase 4A2 Expression Predicts Overall and Disease-free Survival of Human Breast Cancer and is Associated with Estrogen and Progesterone Receptor Status. Horm Cancer 4:208-221, 2013.
    6. Andres, S.A., Brock, G.N., Wittliff, J.L. Interrogating Differences in Expression of Targeted Gene Sets to Predict Breast Cancer Outcome. BMC Cancer 13:326, 2013.
    7. Seelan, R.S., Warner, D.R., Mukhopadyay, P.M., Andres, S.A., Smolenkova, I.A., Wittliff, J.L., Pisano, M.M., Greene, R.M. Epigenetic Analysis of Laser Capture Microdissected Fetal Epithelia. Anal Biochem, Epub ahead of print Jul 30, 2013.

     

    Selected Patents & Licenses:

    1. Judith L. Erb, James G. Downward, IV, John R. Erb-Downward and James L. Wittliff.  Methods and Apparatus for Measurement of the Effect of Test Compounds on Signal Transduction at the Level of Biological Receptors.  United States Patent No: US 6, 300,082 B1, Issued: October 9, 2001.
    2. Judith L. Erb, James G. Downward, IV, John R. Erb-Downward and James L. Wittliff.  Methods and Apparatus for Measurement of the Effect of Test Compounds on Signal Transduction at the Level of Biological Receptors.  United States Patent No: US 20,020,137,055, Issued: September 26, 2002.
    3. Judith L. Erb, James G. Downward, IV, John R. Erb-Downward and James L. Wittliff.  Methods and Apparatus for Measurement of the Effect of Test Compounds on Signal Transduction at the Level of Biological Receptors.  United States Letters Patent No: US 6,962,808 November 8, 2005.   
    4. Mark G. Erlander; Ranelle C. Salunga; Kimberly Stecker and James L. Wittliff  Quantitative Immunohistochemistry for Covalently Modified or Structurally Altered Proteins .  United States Application No. 60/314697, Filing Date August 22, 2001.
    5. Mark G. Erlander; Ranelle C. Salunga; Kimberly Stecker and James L. Wittliff  Quantitative Immunohistochemistry (QIHC) .  United States Application No. 10/080435, Filing Date February 22, 2002.
    6. Mark G. Erlander, Xiao-Jun Ma, Wei Wang and James L. Wittliff.  Breast Cancer Signatures,United States Patent Application No. 10/795092, Filing Date March 5, 2004.
    7. Mark G. Erlander, Xiao-Jun Ma, Wei Wang and James L. Wittliff.  Signatures of ER Status in Breast Cancer, United States Patent Application No. 10/794263, Filing Date March 4, 2004.
    8. Mark G. Erlander, Xiao-Jun Ma, Wei Wang and James L. Wittliff.  Breast Cancer Survival and Recurrence.  United States Application No. 10/871869, Filing Date:  June 18, 2004.
    9. James L. Wittliff, Exclusive Technology License to Asterand, Inc., Detroit, MI, ULRF Research Disclosure 05036, Method for Creation and Maintenance of a Comprehensive Tumor Marker Database and Associated Biological Specimens for the Discovery of Cancer Diagnostics, Prognostics and Therapeutics, Executed October 28, 2005.
    10. James L. Wittliff and Sarah A. Andres.  Methods for Identifying an Increased Likelihood of Recurrence of Breast Cancer.  International Patent Application No. PCT/US2008/006963, date of filing June 3, 2008.
    11. James L. Wittliff, Technology License to Xceed Molecular Corp, Toronto, Canada, ULRF Research Disclosure 07048, Gene Expression Profiles Predicting Clinical Behavior of Breast Cancer.  U.S. Provisional Patent Application No. 60/933,091, date of filing June 4, 2007 (James L. Wittliff & Sarah A. Andres).
    12. James L. Wittliff and D. Alan Kerr II.  Methods of Predicting Disease-Free and Overall Survival of Estrogen Receptor Positive Breast Cancer.  U.S. Provisional Patent Application No. 61/105,297, date of filing October 14, 2008.

     

     

    Document Actions
    Personal tools